New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls.
Read the Q3 2026 report
Saturday, Nov 21, 2026
Export MCRB’s income statement to Excel — free account
Seres Therapeutics, Inc.
MCRBSeres Therapeutics, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $789,000.00, down 99.4% from fiscal 2023.
- Revenue
- +69.0%
- EPS
- n/m
- Free cash flow
- n/m
Quarter to September 2026, against a year earlier
1.24
0.09
−6.77%
After hours trading: 1.25, up 0.81%, last trade Fri 7:35pm Eastern.
Follow MCRB
Alert me
Seres Therapeutics, Inc. (MCRB) news
Stories the last two months, newest first
More headlines
- Seres Therapeutics to Present Preclinical Data for SER-428, an Investigational Live Biotherapeutic Designed to Reduce Risk of Bloodstream Infections in Critically Ill Patients, at IDWeek 2026 GlobeNewswire
- Seres Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Seres Therapeutics to Participate in H.C. Wainwright 28th Annual Global Investment Conference
- Seres Therapeutics Reports Second Quarter 2026 Financial Results and Provides Business Updates, Including Further Action to Reduce Ongoing Facilities Costs
- Seres Therapeutics’ SER-155 Posts 80% Response in Cancer Immunotherapy GI Toxicity Study MarketBeat
- Seres Therapeutics Announces Early Clinical Data Showing Potential for SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis (irEC), a Frequent Adverse Reaction That Forces Many Patients to Halt Cancer Treatment
- Seres Therapeutics to Host Webcast on July 8, 2026, to Discuss Results of Investigator-Sponsored Trial of Seres’ SER-155 in Immune Checkpoint Inhibitor-Related Enterocolitis GlobeNewswire
- We're A Little Worried About Seres Therapeutics' (NASDAQ:MCRB) Cash Burn Rate
- Seres Therapeutics Announces Two Transactions to Strengthen Balance Sheet, Reduce On-Going Lease Costs and Extend Projected Operating Cash Runway Well Into the First Quarter of 2027 GlobeNewswire
- Seres Therapeutics to Participate in H.C. Wainwright 4th Annual BioConnect Investor Conference GlobeNewswire
- Seres Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Updates GlobeNewswire
- Seres Therapeutics Presents Preclinical Data at Digestive Disease Week (DDW) 2026 Supporting SER-603, a Next-Generation Cultivated Live Biotherapeutic Candidate, for Inflammatory Bowel Disease GlobeNewswire
- Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
- Seres Therapeutics Showcases SER-155 Data and Live Biotherapeutic Insights at ESCMID Global 2026
- Seres Therapeutics to Present at CARB-X Investor Day GlobeNewswire
- Seres Therapeutics: Q4 Earnings Snapshot Associated Press Finance
- Seres Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates GlobeNewswire
- Seres Therapeutics Announces Appointment of Richard N. Kender as Executive Chair and Interim CEO; Provides Business Updates GlobeNewswire
- Seres Provides Program and Corporate Updates and Prioritizes Emerging Programs in Inflammatory & Immune Diseases GlobeNewswire
- Seres to lay off staff, pause top program in latest reboot biopharmadive.com
- Particles for Humanity Appoints Marcus Chapman as Senior Vice President and Head of Finance PR Newswire
- Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy GlobeNewswireZacksMT NewswiresMT NewswiresMT NewswiresMT NewswiresMotley FoolMT Newswires
- 3 Beaten-Down Biotech Stocks to Buy for a 2026 Turnaround Zacks
- Seres Therapeutics to Participate in Piper Sandler Healthcare Conference GlobeNewswire
- Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates GlobeNewswire
- Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025 GlobeNewswire